Skip to main content
. 2012 Dec 4;304(2):E211–E221. doi: 10.1152/ajpendo.00374.2012

Table 1.

Measured [Ca2+]i oscillation parameters, as detected by Fluo 4-AM imaging

GPCR Ligand/Gβγ Modulator n GPCR Ligand/Gβγ Modulator Frequency, mHz Amplitude, %Δ
Neuropeptide Y 6 36.33 ± 1.7 9.45 ± 2.0
6 + 40.44 ± 2.2 10.04 ± 2.3
Somatostatin 7 34.47 ± 1.9 7.05 ± 1.6
7 + 27.16 ± 2.9* 8.74 ± 1.0
Gallein 5 44.78 ± 7.8 4.23 ± 3.9
5 + 41.17 ± 7.9 1.32 ± 1.2
mSIRK 5 37.13 ± 7.3 16.82 ± 6.1
5 + 57.83 ± 8.2* 7.10 ± 2.2
NPY + gallein 3 20.54 ± 3.2 21.05 ± 3.4
3 + 25.49 ± 9.4 17.88 ± 6.1
NPY + mSIRK 4 20.65 ± 2.8 13.79 ± 1.7
4 + 32.60 ± 4.8* 5.01 ± 0.6*
SST + gallein 3 18.98 ± 1.9 17.49 ± 4.3
3 + 16.58 ± 5.0 15.61 ± 2.9
SST + mSIRK 4 30.68 ± 3.1 9.76 ± 5.7
4 + 26.57 ± 5.2 11.13 ± 7.0

Data are means ± SE for frequency and amplitude of [Ca2+]i oscillations measured pre- and posttreatment with the specified G protein-coupled receptor (GPCR) ligand and/or Gβγ modulator. Significance was tested using a two-tailed Student's t-test to compare the frequency or amplitude between untreated and treated islets. Significance P< 0.04.